N/A N=12 Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
Bone Metastases · Musculoskeletal Cancer · Soft Tissue Sarcoma
Primary: DVT Incident Rate — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=24 Effect of Deep BLock on Intraoperative Surgical Conditions
Prostate Hypertrophy · Renal Disease
Primary: Surgical Rating Scale — 4; 4.7 units on a scale (1-5) — p=<0.001
Phase 2 N=20 Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Breast Cancer
Primary: Mean Change of Tissue Factor Bearing Microparticles — 102; -618 microparticles per microliter
Phase 2 N=30 Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins
Acute Deep Venous Thrombosis of the Lower Extremity
Primary: Number of Participants With Restored Venous Function — 28 participants
N/A N=100 Detection of Colonic Polyps Via a Large Scale Artificial Intelligence (AI) System
Colonic Polyp
Primary: Number of Additional Polyps Detected by the DEEP System in Real Time Colonoscopy — 0.89 Added polyps detected per colonoscopy
Phase 4 N=90 Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
Deep Vein Thrombosis · Postthrombotic Syndrome
Primary: Number of Participants With Postthrombotic Syndrome as Determined by Villalta Score — 3; 22 Participants — p=<0.0001
Phase 2 N=70 Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Primary: 2-Month Cumulative Incidence of VTE — 5.6; 27.2; 7.2 percent probability — p=0.06
Phase 4 N=91 Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine
Cesarean Section
Primary: Induction to Delivery Interval — 268; 276 seconds
Phase 3 N=2,482 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…
Phase 2 N=82 Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis
Deep Vein Thrombosis
Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity
Phase 3 N=39 The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
Thrombosis, Venous
Primary: Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE) — 0; 0 percentage of participants
Phase 3 N=1,197 Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
Venous Thromboembolism
Primary: Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal…
Phase 2 N=84 A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Deep Vein Thrombosis · Venous Thrombosis
Primary: Relative Change From Baseline in Thrombus Volume Assessed by MRI [Using the Magnetic Resonance Venography (MRV) Method] — -46.6; -51.4 percentage of change
Phase 2 N=25 Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
Venous Thrombosis · Deep Vein Thrombosis
Primary: Pharmacodynamics - Prothrombin Time (PT), Baseline Value — 15.8 Seconds
Phase 4 N=28 Treatment of Upper Extremity Deep-Vein Thrombosis
Deep-Vein Thrombosis
Primary: Percentage of Participants That Died at 3 Months — 8; 0 percentage of participants